David Wagner
Science & Technology ReporterDavid Wagner covers the science and technology beat for KPBS. Before arriving in San Diego, he wrote a research column for The Atlantic magazine's sister site The Atlantic Wire. Other positions found him producing web content for NPR's Arts & Life channel and writing features for the San Francisco Chronicle. He holds English and Political Science B.A.s from UC Berkeley.
MORE STORIES BY THIS AUTHOR
-
A U.S. health agency has awarded San Diego-based Mapp Biopharmaceutical new funding to speed up work on an experimental Ebola drug. -
A new study suggests rising temperatures could cut into California's water supply.
-
After weeks of shying away from the news media, the head of a small San Diego drug company finally talked publicly about his company's experimental Ebola treatment ZMapp.
-
A Liberian doctor's death is the second among the six people treated with ZMapp, an experimental drug to treat Ebola made by a San Diego-based biotech. -
In most cases, Ebola is a death sentence. But most of the infected patients who've taken a San Diego company's experimental drug have lived. Does that mean it works? -
The San Diego company behind an experimental Ebola treatment given to two American health workers last week is now out of the drug. The last available samples have been donated to West Africa.
- In Escondido, a school board member changes her name but not her politics
- Community reacts after school board member comes out as transgender
- SCUBA divers volunteer at San Diego's Birch Aquarium
- San Diego City Council approves parking fees in Balboa Park
- San Diego Unified is getting rid of some K-8 middle schools